Search Results 1891-1900 of 10400 for vardenafil

  1. Want to safeguard the efficacy of antibiotics? There's a team for that. - Mayo Clinic News Network

    The focus of the Enterprise Antimicrobial Stewardship Program is probably not the first thing most Mayo Clinic staff members think about when they start work ...

  2. Publications - David G. Pearson, M.D. - Mayo Clinic

    Han GR, Johnson ER, Jogerst KM, Calderon E, Hewitt WR, Pearson DG, Harold KL. Outcomes of a Large Series of Laparoscopic Ventral Hernia Repairs after Liver ...

  3. A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma - Mayo Clinic

    Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere ...

  4. Mayo Clinic Minute: Erectile dysfunction can signal other problems

    Despite it being a common problem, erectile dysfunction (ED) can make a man feel embarrassed or alone. Seeing a health care provider about the condition is ...

  5. Mayo Clinic

    Share · Tweet . VID-20312303. Home; YouTube-Saint Marys Campus Patient Guide Mayo Clinic Hospital - Rochester Minnesota. Fund research. Save lives.

  6. Trial Using Keytruda as Initial Therapy in the Treatment of Advanced Mycosis Fungoides - Mayo Clinic

    About this study. The purpose of this trial is to evaluate the antitumor activity of Pembrolizumab in patients with advanced mycosis fungoides (MF) as ...

  7. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Participation ...

  8. News - Vlad C. Vasile, M.D., Ph.D. - Mayo Clinic

    Vlad C. Vasile, M.D., Ph.D. Cardiologist. Request an Appointment · Overview · Patient Stories ...

  9. Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment - Mayo Clinic News Network

    Autosomal dominant polycystic kidney disease, which is the fourth most common cause of end-stage kidney disease, requires dialysis or kidney transplant. The ...

  10. Product Surveillance Registry - Mayo Clinic

    About this study. The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic ...